<DOC>
	<DOC>NCT01693029</DOC>
	<brief_summary>The purpose of this study is to show biosimilarity of HX575 epoetin alfa with the US licensed reference product Epogen®/Procrit® when applied subcutaneously. This study is intended to generate data supporting that the efficacy and safety under treatment with HX575 and Epogen®/Procrit® are comparable.</brief_summary>
	<brief_title>Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Patients with end stage renal disease (stage CKD 5d), receiving stable subcutaneous maintenance therapy with Epogen® or Procrit® at least once per week Mean hemoglobin level between 9.0 11.5 g/dL during the screening period Adequate iron substitution Contraindications for Erythropoiesis Stimulating Agent (ESA) therapy History of Pure Red Cell Aplasia (PRCA), or antierythropoietin (EPO) antibodies Known Human Immunodeficiency Virus (HIV) or Hepatitis B infection Hepatitis C infection on an active treatment Symptomatic congestive heart failure (New York Heart Association [NYHA] class III and IV) Unstable angina pectoris, or cardiac infarction during the last 6 months prior to randomization Percutaneous coronary intervention, or coronary artery bypass grafting during the last 6 months prior to randomization History of malignancy of any organ system Systemic lupus erythematous Immunocompromized patients Other In/Exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>erythropoietin alfa</keyword>
	<keyword>CKD 5d</keyword>
</DOC>